BUMETANIDE Drug Patent Profile
✉ Email this page to a colleague
When do Bumetanide patents expire, and what generic alternatives are available?
Bumetanide is a drug marketed by Gland Pharma Ltd, Hospira, Lupin Ltd, MSN, Qilu Pharm Hainan, Sagent, Teva Parenteral, West-ward Pharms Int, Amneal Pharms Co, Appco, Heritage Pharma, Rising, Sandoz, Taro, Upsher Smith Labs, and Zydus Pharms. and is included in seventeen NDAs.
The generic ingredient in BUMETANIDE is bumetanide. There are six drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the bumetanide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bumetanide
A generic version of BUMETANIDE was approved as bumetanide by SAGENT on January 27th, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BUMETANIDE?
- What are the global sales for BUMETANIDE?
- What is Average Wholesale Price for BUMETANIDE?
Summary for BUMETANIDE
| US Patents: | 0 |
| Applicants: | 16 |
| NDAs: | 17 |
| Finished Product Suppliers / Packagers: | 26 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 29 |
| Patent Applications: | 4,878 |
| Drug Prices: | Drug price information for BUMETANIDE |
| Drug Sales Revenues: | Drug sales revenues for BUMETANIDE |
| What excipients (inactive ingredients) are in BUMETANIDE? | BUMETANIDE excipients list |
| DailyMed Link: | BUMETANIDE at DailyMed |
See drug prices for BUMETANIDE
Recent Clinical Trials for BUMETANIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mayo Clinic | Phase 2 |
| Yale University | Phase 1 |
| Roche Diagnostics | Phase 4 |
Pharmacology for BUMETANIDE
| Drug Class | Loop Diuretic |
| Physiological Effect | Increased Diuresis at Loop of Henle |
Medical Subject Heading (MeSH) Categories for BUMETANIDE
Anatomical Therapeutic Chemical (ATC) Classes for BUMETANIDE
US Patents and Regulatory Information for BUMETANIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Pharms | BUMETANIDE | bumetanide | TABLET;ORAL | 202900-002 | Apr 30, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Upsher Smith Labs | BUMETANIDE | bumetanide | TABLET;ORAL | 209916-001 | Jan 23, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | BUMETANIDE | bumetanide | TABLET;ORAL | 202900-003 | Apr 30, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Upsher Smith Labs | BUMETANIDE | bumetanide | TABLET;ORAL | 209916-002 | Jan 23, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Gland Pharma Ltd | BUMETANIDE | bumetanide | INJECTABLE;INJECTION | 216434-001 | May 26, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Heritage Pharma | BUMETANIDE | bumetanide | TABLET;ORAL | 074225-003 | Apr 24, 1995 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
